Homepage

Exploring a better tomorrow

We explore. Driven by our passion for science. Boosted by our unique infrastructure. We sound out the frontiers. We expand our knowledge in various nuclear areas. However many horizons we may explore, we always pursue the same objective: developing innovative applications for society. Why do we strive for this objective? Because we are convinced that, with one of the smallest elements on earth, the atom, we can make the biggest difference for society. Both now and in the future.

Discover more about SCK CEN

In the picture

SCK CEN - NURA (2019)

NURA

With its NURA project, SCK CEN significantly increases its contribution to the fight against cancer. By pooling its knowledge and expertise in terms of radiopharmaceuticals, NURA contributes to the development of the next-generation radiopharmaceuticals. More specifically, NURA performs game-changing research into radiopharmaceuticals for treating different types of cancer in cooperation with clinical and industrial partners.

2019 MYRRHA - SCK CEN

MYRRHA

SCK CEN works actively on the design and construction of a new multi-purpose research plant: MYRRHA, which stands for Multi-purpose HYbrid Research Reactor for High-tech Applications.  MYRRHA is a versatile research infrastructure but above all unique. It is the world's first research reactor driven by a particle accelerator.

RECUMO - SCK CEN - IRE (2019)

RECUMO

With the public-public partnership RECUMO, SCK CEN and the National Institute for Radio Elements (IRE) reach out to one another. SCK CEN will decontaminate the current and future highly radioactive residues and thus reduce the stock. In this way, RECUMO contributes to the security of supply of medical radio-isotopes, which are indispensable in the fight against cancer.

Latest news

SCK CEN - Ontmanteling cyclotron Telix (2021)
18 October '21

First Cyclotron removed from Seneffe Production Facility by SCK CEN

Decommissioning the first step in Telix Pharmaceuticals’ plan to commence production of medical radioisotopes in Europe

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) and SCK CEN (the Belgian Nuclear Research Centre) today announce that the first of two cyclotrons has been removed from the Company’s licensed radiopharmaceutical production facility in Brussels (Seneffe), Belgium. This follows the Belgian Agence Fédérale de Contrôle Nucléaire (AFCN) acceptance of Telix’s decommissioning dossier in July, submitted with the support of SCK CEN.

More news

Health

From cancer research to the impact of radioactivity on the body: SCK CEN’s research knows no boundaries.

Environment

SCK CEN is working on many applications to protect people and the environment, now and in a distant future, against ionising radiation.

Society

Any research conducted by SCK CEN has a social added value, but society is also the very subject of one specific research field.

Materials

Thanks to its knowledge in material aging, SCK CEN accurately predicts how materials (will) behave in a nuclear reactor.

Technology

SCK CEN boosts innovation in nuclear technology in various ways.

Safety

Safety is our priority, radiation protection our keyword. SCK CEN measures, monitors and analyses.

2018_ACA-Training-Education

SCK CEN Academy: a matter of acquiring and sharing knowledge

Making progress by letting our scientific curiosity prevail. This is what our research centre is about. This reasoning leads to breakthroughs. However, we can only make a difference if we share our knowledge with others. This is why SCK CEN and its Academy offer a whole range of training courses and schooling.
Discover our offer

Events & fairs

Discover all our events